May 28, 2024Open Access

Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases

OMOscar MammolitiGalapagos (Belgium)SMSébastien L. X. MartinaGalapagos (Belgium)PCPieter ClaesGalapagos (Belgium)

Key Points

Key points are not available for this paper at this time.

Abstract

Tyrosine kinase 2 (TYK2) mediates cytokine signaling through type 1 interferon, interleukin (IL)-12/IL-23, and the IL-10 family. There appears to be an association between TYK2 genetic variants and inflammatory conditions, and clinical evidence suggests that selective inhibition of TYK2 could produce a unique therapeutic profile. Here, we describe the discovery of compound

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Mammoliti et al. (Tue,) studied this question.

synapsesocial.com/papers/68e680e5b6db643587609a98 https://doi.org/https://doi.org/10.1021/acs.jmedchem.4c00769

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper